Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March.
Ryoncil (remestemcel-L-rknd) is the first and only FDA-approved mesenchymal stromal cell (MSC) product in the US for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
Mesoblast said it has onboarded more than 25 transplant centres since the product launch and expects to complete the onboarding process across all 45 priority transplant centres that account for approximately 80 per cent of US paediatric transplants during this quarter.
It said insurance coverage for Ryoncil continues to expand. Federal Medicaid coverage by the Centers for Medicare and Medicaid (CMS) is in place and mandatory fee-for-service Medicaid coverage for Ryoncil became effective July 1 in all US states.
Mesoblast chief executive Dr Silviu Itescu said, “We are pleased with the commercial launch activities of Ryoncil in the first quarter post-launch and look forward to updating on the current quarter's progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major US transplant centres.”